Analyst Upgrade Ignites Duchenne's Muscular Dystrophy Research Firm's Shares

Solid Biosciences' shares are up by more than 40% after Chardan Capital Markets upgraded the firm's shares from "neutral" to "buy" and raised its price target from $7.50 to $10.00/share. read more >

InMode Reports Solid Q2 Earnings and Appoints Paula Abdul as Brand Ambassador

InMode Ltd. reported Q2/19 earnings and announced that international pop superstar Paula Abdul will be its brand ambassador sending shares "Straight Up" 15% as investors "Rush Rush" to purchase shares today. read more >

Deciphera's Shares Open 115% Higher on Phase 3 Ripretinib Results

Deciphera Pharmaceuticals announced positive top-line results from the INVICTUS pivotal phase 3 clinical study of ripretinib in patients with advanced gastrointestinal stromal tumors. read more >

Biotech's DMD Therapeutic 'Solidifies the Ground for Potential Pivotal Design'

Research Report
The latest development concerning this clinical asset and other Q2/19 highlights are provided in an H.C. Wainwright & Co. report. read more >

Amgen Shares React Favorably to Enbrel Patent Case Victory

Amgen shares traded 56% higher on news that the company has won its Enbrel (etanercept) patent court case. read more >

Puma Biotech Shares Up More Than 20% on Q2 Earnings and Breast Cancer Drug Sales

Shares in Puma Biotechnology traded 20% higher after the company released Q2/19 earnings and reported positive NERLYNX revenue growth. read more >

Avedro Shares Looking Up 35% with Glaukos Merger

Avedro Inc. and Glaukos Corp. announced that the firms' boards of directors have executed a definitive merger agreement. The all-stock deal is expected to close in Q4/19. read more >

Guardant Health Reports Quarterly Revenue Up 178%

Guardant Health Inc. reported strong growth for Q2/19 versus the same period last year and raised its full-year 2019 revenue guidance to $180190 million. read more >

Allakos Shares Double on AK002 Phase 2 Results and Earnings

Allakos Inc. shares soared as the company reported Q2/19 earnings and announced positive results from its phase 2 study for its AK002 inhibitor used in the treatment of eosinophil and mast cell related diseases. read more >

Tandem Increases Unit Sales of t:slim X2 Insulin Pumps 290% Worldwide

Tandem Diabetes Care's second quarter earnings highlighted a 290% increase in unit sales of its t:slim X2 insulin pumps that feature integrated continuous glucose monitoring and remote software update capability. read more >

Expert Investing Ideas

"The market for DRRX's POSIMIR could be substantial."

–Brian Marckx, Zacks Small-Cap Research

"DRRX's current valuation is an interesting buying opportunity."

–Francois Brisebois, Laidlaw & Company

"SPR is the number one cannabis stock to own today."

–Cynthia Berryman, Financial News Now

"DRRX's Posimir comes back in play."

–Ed Arce, H.C. Wainwright & Co.

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

Biotech's Mosquito Test 'Gains Market Acceptance'

Research Report
This West Nile virus test and others including cancer diagnostic tests in the Utah company's pipeline are discussed in an H.C. Wainwright & Co. report. read more >

Biotech 'Thinking Several Steps Ahead with Optimizing IVR Quality Control'

Research Report
The company's latest science, presented at a recent conference, is discussed in a ROTH Capital Partners report. read more >

Led by Sales of HETLIOZ, Vanda Increases Quarterly Revenues by 25%

Shares of Vanda Pharmaceuticals traded nearly 30% higher after the company released Q2/19 earnings and positive sales trends for both HETLIOZ and Fanapt. read more >

Gaia Grow Corp. Plants 1,494 Acres of Hemp in Canada and Plans First Harvest in 2 Months

Contributed Opinion
Gaia Grow Corp. CEO Frederick Pels speaks with Peter Epstein of Epstein Research on the day his company begins trading on the TSX Venture Exchange. read more >